KUALA LUMPUR, March 21 (Bernama) -- A-Bio has invested RM7 million (US$1.8M) in Clinipath Malaysia Sdn Bhd (Clinipath) as part of the efforts of both companies to catalyse the digitalisation of the healthcare industry in Malaysia. Clinipath, wholly owned by Malaysian Genomics Resource Centre Berhad (Malaysian Genomics), is one of Malaysia’s leading pathology service providers with a nationwide network of clinical laboratories serving doctors in hospitals, clinics and research laboratories. 
 
The investment made by A-Bio will help Clinipath to improve its IT infrastructure, expand laboratories in key locations and develop new clinical tests. Notably, the investee is venturing into modernisation of pathology through further automation of its workflow processes, and opening channels to scale up its operations in the local and regional markets.   
 
“We are impressed with Clinipath’s innovation-based growth plan and we believe that the management is more than capable of growing the company to a higher level. The target market is huge and the impact to the country is significant given that the country is seeing growth in its population and the high prevalence of chronic diseases. Bridging the gap with the digitisation of healthcare services, A-Bio hopes to leapfrog Malaysia into the use of digital technology to help mitigate rising healthcare delivery costs. We are confident that Clinipath will be able to grow itself by expanding into ASEAN and other developed markets. Our investment in Clinipath is in line with our mandate to build and nurture the growth of Malaysian market leaders in our niche focus areas of high-tech industry, with emphasis on balancing profitability and socio-economic multipliers,” said Dr Norida Abdul Rahman, Managing Director of A-Bio.
 
“Malaysia’s clinical pathology industry offers tremendous growth potential. Improving pathology testing capabilities, including developing new technologies and tests using the latest genetics and genomics resources, will contribute directly to higher quality healthcare services in clinics and hospitals. We are pleased that A-Bio is joining forces with us to play an important role in enhancing Malaysia’s healthcare industry through this critical support service, and we look forward to working together to make this a reality,” said Sasha Nordin, Chief Operating Officer, Malaysian Genomics.

About A-BIO Sdn Bhd (A-Bio)
A-Bio is a strategic investment company established by the Malaysian government in 2009 with mandate to catalyse the growth of innovative high technology industries via impact investing. A-Bio focuses its investment in high value-added and high technology industries namely bio-industry, emerging industry such as industry 4.0 technology and green technology. A-Bio is a wholly-owned subsidiary of the Malaysian Industry-Government Group for High Technology (MIGHT).

About Clinipath Malaysia Sdn Bhd (Clinipath)

Clinipath is one of Malaysia’s largest independent pathology service providers, with a nationwide network of 17 branches. It offers a complete range of fast, accurate and reliable pathology testing services, with over 1,300 tests. It has been ISO 15189 accredited since 2010. Clinipath is a wholly-owned subsidiary of public-listed Malaysian Genomics Resource Centre Berhad.  

Source : Clinipath Malaysia Sdn Bhd

FOR MORE INFORMATION, PLEASE CONTACT:
Clinipath Malaysia Sdn Bhd
Name : Joseph Neo
Tel : +60322831820
Email : joseph@mgrc.com.my

A-Bio Sdn Bhd 
Name : Karim Khaidi
Tel : +60193332314 
Email : karim@abio.my

--BERNAMA